Atlas Lithium Corporation (OTCQB: ATLX) is quickly emerging as one of the most actively traded stocks on the bulletin boards. The Brazilian miner believes that it holds the largest portfolio of lithium mineral exploration properties in Brazil, and that it is among the largest holders by size and breadth in exploration projects for battery metals globally. The Company’s Minas Gerais Lithium Project is located right next to Sigma Lithium currently trading for $35 per share on the Nasdaq. The Company has big plans for growth and he has already taken steps to uplist Atlas Lithium to the Nasdaq stock exchange using EF Hutton as underwriter.
Atlas Lithium is led by MIT and Harvard Alum CEO Marc Fogassa who has an ambitious goal of making Atlas a billion-dollar lithium Company and he has been very successful in attracting a powerful high caliber management team and has been busy building up the Company’s bod recently bringing on wall street executive Stephen R. Petersen as a new board member. The Company also brought on CFO Gustavo Pereira de Aguiar, former controller of Jaguar Mining, Inc, a Canadian company with two producing gold mines in the state of Minas Gerais in Brazil and current market capitalization of approximately $270 million.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Atlas Lithium Corporation (OTCQB: ATLX) Operating out of executive offices in Beverly Hills, California and Minas Gerais, Brazil, has one of the largest exploration projects for lithium and other battery minerals in Brazil. The Company is focused on advancing, expanding, and developing its portfolio of mineral rights for battery metals which currently includes 72,344 acres (293 km2) for lithium in 59 mineral rights, 54,950 acres for nickel (222 km2) in 15 mineral rights, 30,054 acres (122 km2) for rare earths in seven mineral rights, 22,050 acres (89 km2) for titanium in seven mineral rights, and 13,766 acres (56 km2) for graphite in three mineral rights. Atlas Lithium believes that it holds the largest portfolio of lithium mineral exploration properties in Brazil, and that it is among the largest holders by size and breadth in exploration projects for battery metals globally. The company also owns approximately 44% of Apollo Resources Corp. (private company; iron) and 24% of Jupiter Gold Corp. (OTCQB: JUPGF). Several weeks ago, the Company engaged international investor relations specialists MZ Group to lead a comprehensive strategic investor relations and financial communications program across all key markets.
The Company is led by CEO Marc Fogassa, a high-level executive with extensive experience in venture capital and public company chief executive management. He has served on boards of directors of multiple private companies in various industries, and is a regular speaker internationally. Mr. Fogassa graduated with two Bachelor of Science degrees from MIT and from Harvard Medical School with a Dr. of Medicine. Mr. Fogassa owns 2,877,789,671 shares of ATLX.
Atlas Lithium’s 100% owned Minas Gerais Lithium Project currently encompasses 52 mineral rights spread over approximately 56,078 acres (227 km2) located in the northern part of the State of Minas Gerais, Brazil, in the municipalities of Araçuai, Itinga, Coronel Murta, Rubelita, Taiobeiras, and Virgem da Lapa. Several of the Company’s mineral rights are located adjacent to or near mineral rights that belong to Sigma Lithium currently trading for $35 per share on the Nasdaq which has demonstrated through extensive drilling the presence of lithium deposits totaling over 80 million tons, according to its publicly available filings. The Company’s exploratory work to date in some mineral rights in its Minas Gerais Lithium Project has determined the existence of hard rock pegmatites with lithium mineralization. Given the proximity to areas of economically significant lithium deposits, Company technical experts believe that one or more areas of its Minas Gerais Lithium Project may also contain similar lithium deposits.
Currently Atlas Lithium is drilling the Neves Area at its flagship Minas Gerais Lithium Project. SLR International Corporation (SLR), a premier independent mineral resource evaluation firm, recently authored a preliminary technical report on the Neves Area showcasing its favorable geology for lithium and its potential. Additionally, an initial metallurgical study at SGS-Geosol, a first-tier independent analytical laboratory, has shown ease in recovery of lithium concentrate from samples obtained at the Neves Area. The Company’s geological and metallurgical teams are working closely with counterpart experts from SLR to produce the Company’s maiden resource report, followed by a preliminary feasibility study, as Atlas Lithium works toward its revenue-generating goal of entering lithium concentrate production.
To Find out the inside Scoop on ATLX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Atlas Lithium owns 46.17% of the common shares of Apollo Resources Corporation, a private company currently primarily focused on the development of its initial iron mine, expected to start operations and revenues in early 2023. The Company also own approximately 24.56% of Jupiter Gold Corporation a company focused on the development of gold projects and of a quartzite mine, and whose common shares are quoted on the OTCQB under the symbol “JUPGF”. The quartzite mine is expected to start operations and revenues in 2022. Currently JUPGF trades at $1.15 JUPGF quartzite mine is expected to start operations and revenues in 2022.
On November 2 Atlas Lithium provided a corporate update in conjunction with the filing of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2022: The Company began to implement its current business strategy of focusing on the exploration of strategic minerals in 2018. From 2018 through 2022, the Company significantly expanded its portfolio of mineral rights for battery metals which currently includes 72,344 acres (293 km2) for lithium in 59 mineral rights, 54,950 acres for nickel (222 km2) in 15 mineral rights, 30,054 acres (122 km2) for rare earths in seven mineral rights, 22,050 acres (89 km2) for titanium in seven mineral rights, and 13,766 acres (56 km2) for graphite in three mineral rights. Atlas Lithium believes that it holds the largest portfolio of lithium mineral exploration properties in Brazil, and that it is among the largest holders by size and breadth in exploration projects for battery metals globally.
In the third quarter of 2022, the Company filed its first geological report that highlighted the potential of its 100%-owned Minas Gerais Lithium Project and was prepared by independent expert firm SLR International Corporation in compliance with Regulation S-K 1300 (“SLR Report”) applicable to U.S. reporting companies, bringing significant credibility to the Company’s lithium program. Importantly, the SLR Report indicated that, commercial-grade lithium concentrate was able to be produced at a well-respected third-party testing facility using mineralized samples from the Company’s project. Atlas Lithium’s purchase of additional lithium mineral rights during 2022 is reflected by the $4.8 million of intangible assets as of September 30, 2022, which is an increase of 271% from $1.3 million as of 2021 year-end. In addition, the Company’s net stockholder’s equity stood at $2.6 million as of September 30, 2022, which represents an increase of 468% from $0.5 million as of December 31, 2021. Finally, the Company continues to actively work towards the uplisting of its common stock to the Nasdaq Capital Market.
CEO Marc Fogassa stated: “We are executing upon our flagship Minas Gerais Lithium Project with the continuation of our drilling program being our primary focus in the second half of 2022″Our Neves Area, one of the 52 mineral rights that comprise this exploration project, has yielded very promising results for lithium mineralization with potential for future production of commercial-grade lithium concentrate. We also made several recent additions to our executive team that will be critical to our continued delineation of our mineral resources and development of our projects. As part of our strategy to capitalize on the accelerated worldwide demand for battery minerals used in electric vehicles, we have begun discussions with large, global companies seeking to secure our lithium supply. Given Atlas Lithium owns the largest footprint of lithium areas in Brazil, we are uniquely positioned to establish Atlas Lithium as a leader in one of the world’s premier regions for lithium.”
Currently trading at a $39 million market valuation ATLX has 3,385,151,300 shares outstanding of which 1,222,982,873 are restricted, leaving 2,187,513,979 free trading BMIX shares. The Company has $1.8 million in assets and under $1 million in debt. *Not including equity stakes in Apollo Resources, and Jupiter Gold Corporation (OTCQB: JUPGF) BMIX traded as high as $0.10 in early 2021 and recently reversed off $0.0039 lows after the seller that decimated the share price in recent months closed out their position. BMIX Minas Gerais Lithium Project intersects the property of Sigma Lithium Corp currently trading for $35 on the Nasdaq. Sigma has demonstrated through extensive drilling the presence of lithium deposits totaling over 20 million tons, according to its publicly available filings. Besides lithium, Brazil Minerals’ portfolio of exploration properties for other battery metals includes 59,700 acres (234 km2) for nickel, 30,009 acres (121 km2) for rare earths, 22,050 acres (89 km2) for titanium, and 14,507 acres (59 km2) for graphite. The Company believes that it has one of the largest exploration footprints for battery metals among publicly listed companies.We will be updating on ATLX when more details emerge so make sure you are subscribed to Microcapdaily.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in ATLX either long or short and we have not been compensated for this article.
LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.
GAMMABODY™ PLATFORM
LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.
To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.
In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.
My big % winning day trade today was $LVTX. All I did was follow the system. It has a small float. Fresh meet never pumped before. Big News out. Giant volume. Why I jumped in early and took profits on the spike in volume. pic.twitter.com/2knPeC5RHz
As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates.
The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.
$LVTX $66mil mcap, $133mil in cash at the end of December, cash runway into 2026, median price target $13 (443% upside)
Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.
Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.
$LVTX has three gamma-delta t cell drug candidates in early-stage trials, including collaboration with $SGEN for solid tumors.
In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.
We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development. The clinical-stage biopharmaceutical company has entered into a take-private transaction with MPM BioImpact, representing a significant milestone for Reunion Neuroscience. The transaction is valued at $13.1 million, a 43.1% premium to Reunion’s common shares’ 30-day volume-weighted average price.
Going private is a significant step for Reunion Neuroscience, as it means that a sizeable private-equity group or consortium of private-equity firms will purchase or acquire the stock of the publicly traded corporation.
To Discover the Inside Scoop on REUN, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Under the terms of the Arrangement Agreement, all holders of outstanding common shares of Reunion will be entitled to receive $1.12 in cash for each share held immediately before the effective time of the Arrangement. However, the agreement’s closing is subject to several conditions, which must be met before the transaction can be completed.
— JC Capital Consultants (@CapitalJc) June 1, 2023
Hostile takeover?
While management and the board think it is a significant milestone achieved, others think differently – an investor rights law firm, Halper Sadeh LLC, is currently investigating it… The sale of Reunion Neuroscience to affiliates of MPM BioImpact for $1.12 per share in cash is currently being investigated by Halper Sadeh LLC.
The investigation concerns whether Reunion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Reunion shareholders; (2) determine whether MPM is underpaying for Reunion; and (3) disclose all material information necessary for Reunion shareholders to assess and value the merger consideration adequately. On behalf of Reunion shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
$Reun Reunion Neuro we are buying this little Gem up. Could see this at $3 in coming months. Great acquisition $13 ,million just for starters . Watch this space 💎
Reunion Neuroscience’s stock performance has been relatively volatile in recent years. The stock’s median target price, according to analysts’ forecasts, is $5.00, but there is a wide range of estimates, with a high of $20.00 and a low of $0.73. The current consensus among polled investment analysts is to buy $REUN stock. However, they’re a pre-revenue clinical-stage biopharmaceutical company, which means the last earnings reported a loss in the current quarter’s earnings per share – they’ve yet to generate any significant revenue. Until recently, shareholders experienced a significant decline in the stock’s value this year and were down ~54% prior to the acquisition. There are ~9M shares in the float, with ~28% and ~13% held by insiders and institutional investors, respectively.
Solid scalp for a quick win on $REUN. Low float but not really that much volume so it appears to be done and tanking accordingly. Time for this old dog to go into town.
Overall, investors should carefully consider the potential risks and rewards associated with investing in Reunion Neuroscience, considering the wide range of price estimates and the company’s current financial performance. Thorough research and the advice of a financial professional are recommended before making any investment decisions.
We will update you on REUN when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601. They tested it on lymphoma cells in the lab, and the results showed that MT-601 can kill lymphoma cells resistant to another treatment called CD19 CAR T therapy, which is fascinating news considering many patients who receive CD19 CAR T therapy still experience a relapse within a year.
“We have recently developed a long-term in vitro model to monitor the interaction of T cells with cancerous cells. Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited the growth of lymphoma cells as well as the growth of CD19 CAR-resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics. Marker has posted further details about this preclinical study on the Investor Relations section of its website.
$MRKR Marker Therapeutics reveals positive pre-clinical results of its MT-601 MultiTAA-Specific T Cell Product Candidate in lymphoma cells.
Dr. Smith continued, “Specifically, we have developed an in vitro model which reproduces the CD19 antigen-negative tumor that causes relapse and observed the following:
To Discover the Inside Scoop on MRKR, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
In this in vitro model, 98% of lymphoma cells were eliminated after a CD19-targeting CAR T cell product was administered.
— DayRanger – Investors Underground (@DayRanger) May 31, 2023
While the CAR T cells significantly controlled lymphoma cell growth, we observed that three weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells resistant to CD19 CAR T cell administration started to grow.
These CD19 CAR-resistant lymphoma cells were tested for CD19 expression. They were shown to be negative for the CD19 surface antigen, which explained why they were no longer controlled with a second administration of anti-C19 CAR T cells, thus recapitulating the antigen-negative relapse observations in CAR relapsed/refractory lymphoma patients.
However, when MT-601, with its broad antigen recognition (Survivin, NY-ESO-1, WT-1, PRAME, MAGE-A4, SSX2), was added to this anti-CD19 CAR T cell resistant cell population, complete growth inhibition was observed.
These data highlight that MT-601 can potentially eliminate CD19 CAR T cell refractory tumors, indicating that MT-601 might offer a viable therapeutic option for lymphoma patients that have relapsed from previous CAR T cell interventions.”
MT-601 targets multiple substances on cancer cells and may provide longer-lasting results than CD19 CAR T therapy. Marker Therapeutics has started a clinical trial to test MT-601 on lymphoma patients who have relapsed after CD19 CAR T therapy or cannot receive it. The early lab results showed that MT-601 could inhibit the growth of lymphoma cells, including those resistant to CD19 CAR T therapy. The initial results have shown remarkable promise, and the team is thrilled to advance the testing of MT-601 in further clinical trials to evaluate its effectiveness and safety.
About Marker Therapeutics, Inc.
Marker Therapeutics is a company currently in the advanced stages of clinical research for developing innovative treatments in immuno-oncology. Their primary focus is on creating next-generation immunotherapies that utilize T cells, a type of immune cell, to target and fight against hematological malignancies (cancers of the blood, such as leukemia and lymphoma) and solid tumors (cancers that form in tissues or organs). These therapies aim to harness the immune system’s power to specifically recognize and eliminate cancer cells, offering potential new treatment options for patients with these types of cancers.
Marker Therapeutics has an outstanding total of 8.8M shares and presents a relatively small float of 6.64M shares available for public trading. Insiders hold approximately 12.82% of the shares, while institutional investors hold around 22.63%. Examining their trading history, the average volume typically hovers around 100,000 shares. In light of the positive news today, the trading activity trended much higher, with an impressive 27M shares traded at time of writing. This translates to a 270-fold increase compared to their average volume, also 4x their float.
— Nick Sullivan Life & Medicare Agency (@SprouttSales) May 31, 2023
It is essential to recognize the high volatility and rapid movements associated with Marker Therapeutics’ stock, primarily driven by the limited availability of shares. Such stocks tend to attract the interest of day and swing traders, given their propensity for swift gains or losses based on trading strategies. As evidence, a single positive news catalyst in the biotech sector can trigger a substantial surge in stock price and exponentially increase trading volume to unprecedented levels.
We will update you on MRKR when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.